🇺🇸 FDA
Patent

US 10479830

Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10479830 (Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines) held by CHEMOMAB LTD. expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHEMOMAB LTD.
Grant date
Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P1/10